Therapeutic efficacy of Pudilan Xiaoyan Oral Liquid (PDL) for COVID-19 in vitro and in vivo
Wei Deng, Yanfeng Xu, Qi Kong, Jing Xue, Pin Yu, Jiangning Liu, Qi Lv, Fengdi Li, Qiang Wei & Linlin Bao
Signal Transduction and Targeted Therapy volume 5, Article number: 66 (2020)
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has rapidly swept through the worldwide, with more than 3 million confirmed cases. Until now, no vaccine or effective therapeutic measures are provided to prevent the SARS-CoV-2 infection. Existing medicines have some strong advantages on pharmacokinetics, known side effects, safety and dosing regimens.1 Although remdesivir and chloroquine could effectively inhibit the replication of SARS-CoV-2 in vitro,2 no medicine candidates have been evaluated in vivo by using animal models with SARS-CoV-2 infection.